Fiche du document
2015
- doi: 10.18632/oncotarget.4160
- issn: 1949-2553
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.18632/oncotarget.4160
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/26164081
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1949-2553
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_3FE518F2703B9
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Carcinoma Cancers Malignancy (Cancer) Malignant tumorsCiter ce document
R. Cohen et al., « Targeting cancer cell metabolism in pancreatic adenocarcinoma. », Serveur académique Lausannois, ID : 10.18632/oncotarget.4160
Métriques
Partage / Export
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second leading cause of cancer death by 2030. Current therapeutic options are limited, warranting an urgent need to explore innovative treatment strategies. Due to specific microenvironment constraints including an extensive desmoplastic stroma reaction, PDAC faces major metabolic challenges, principally hypoxia and nutrient deprivation. Their connection with oncogenic alterations such as KRAS mutations has brought metabolic reprogramming to the forefront of PDAC therapeutic research. The Warburg effect, glutamine addiction, and autophagy stand as the most important adaptive metabolic mechanisms of cancer cells themselves, however metabolic reprogramming is also an important feature of the tumor microenvironment, having a major impact on epigenetic reprogramming and tumor cell interactions with its complex stroma. We present a comprehensive overview of the main metabolic adaptations contributing to PDAC development and progression. A review of current and future therapies targeting this range of metabolic pathways is provided.